Qual é o preço para AlloVir, Inc. (ALVR)

O preço para AlloVir, Inc. (ALVR) é $9.81

Qual é a capitalização de mercado para AlloVir, Inc. (ALVR)

A capitalização de mercado para AlloVir, Inc. (ALVR) é $48.68M

Lucros de AlloVir, Inc. (ALVR)

AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to researching and developing allogeneic, "off-the-shelf" multi-virus specific T-cell (VST) therapies. Its primary goal is to prevent and treat severe diseases caused by viral infections. The company's lead product, posoleucel, is an allogeneic, ready-to-use VST therapy designed to combat several significant viruses, including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Beyond this flagship candidate, AlloVir's pipeline features additional investigational treatments in various stages of development. These include ALVR106, which targets respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109, developed to address SARS-CoV-2 and COVID-19; ALVR107, for treating hepatitis B; and ALVR108. Established in 2013, the company was initially known as ViraCyte, Inc. before officially rebranding as AlloVir, Inc. in May 2019. Its headquarters are located in Waltham, Massachusetts.

Ano	Lucros	Alterar
2026 (TTM)	$-54.46M	-7.33%
2024	$-58.77M	-69.16%
2023	$-190.54M	12.76%
2022	$-168.98M	-1.16%
2021	$-170.96M	144.98%
2020	$-69.78M	192.73%
2019	$-23.84M	881.03%
2018	$-2.43M	0.00%

Ano

Lucros

Alterar

2026 (TTM)

$-54.46M

-7.33%

2024

$-58.77M

-69.16%

2023

$-190.54M

12.76%

2022

$-168.98M

-1.16%

2021

$-170.96M

144.98%

2020

$-69.78M

192.73%

2019

$-23.84M

881.03%

2018

$-2.43M

0.00%

Empresa	Lucros	Diferença de Lucros	País
Vertex Pharmaceuticals Incorporated VRTX.US	$5.27B	-9,786.00%	US
Argenx SE ARGX.US	$1.95B	-3,681.87%	NL
CSL Limited CSL.AX	$1.61B	-3,064.22%	AU
Lonza Group AG LONN.SW	-	-	CH
Moderna, Inc. MRNA.US	$-3.09B	5,568.48%	US

Empresa

Lucros

Diferença de Lucros

País